Could a common heart drug tame nosebleeds in a rare bleeding disorder?

NCT ID NCT04113187

First seen May 24, 2026 · Last updated May 24, 2026

Summary

This study looked at whether propranolol, a beta-blocker usually used for heart conditions, can help people with hereditary hemorrhagic telangiectasia (HHT) who have frequent nosebleeds. Fifteen adults with HHT took propranolol for three months. The main goal was to see if the total time spent nosebleeding each month went down. The study also tracked how often nosebleeds happened, changes in skin spots, blood levels, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU de Bordeaux - service de médecine interne

    Bordeaux, France

Conditions

Explore the condition pages connected to this study.